Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Atazanavir is the active ingredient of these drugs:
Australia Austria Brazil Canada Cyprus
Atazanavir is also found within below combination drugs:
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):